Please ensure Javascript is enabled for purposes of website accessibility

The Reason Behind Juno Therapeutics Inc.'s Tumble

By Sean Williams - Jun 17, 2015 at 3:28PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The reason for Juno Therapeutics' tumble may not be obvious, but it's also probably not a huge concern.

What: Shares of Juno Therapeutics (JUNO), a clinical-stage biopharmaceutical company focused on developing cancer immunotherapy products based on its CAR-T targeted technology, tumbled as much as 12% following the expiration of its lockup period.

So what: Lockup expirations aren't something that usually make a lot of news, but here's how they work. When a company goes public, as Juno Therapeutics did about six months ago, there's a 180-day period where insiders of the company aren't allowed to sell their shares. Additionally, when a company offers shares to the public for the first time, they typically only offer a small percentage of the available shares for trading. This can also increase demand for a stock and boost its share price.

In Juno's case, it offered just 11,022,917 shares when it priced at $24, although it carries 77,939,023 shares outstanding. These nearly 67 million additional shares are released for trading once the 180 days is up -- which happened today. Some view lockups as dilutive to existing shareholders (though they really aren't), but the bigger concern is that insiders can now cash in shares of their common stock. This clearly has investors bothered following a better than 100% return since its IPO pricing at $24.

Now what: Lockup expiration woes are rarely an event that's talked about for longer than a few days, so while Juno Therapeutics' shares are probably going to remain volatile, the event itself has no bearing on the company's business model or outlook. In other words, a lockup expiration isn't going to change your investing thesis.

The real question that investors need to be asking is if CAR-T based cancer immunotherapies are the wave of the future or just a "fad" within the drug discovery process. Honestly, it's hard to tell at this point because Juno Therapeutics' pipeline is so young. It has 10 identified compounds targeted at a mixture of blood cancers and solid tumors, but only six are in clinical studies, and of those, they're all phase 1 trials or phase 1/2 studies. We're going to need quite some time to get a true bead on whether or not Juno's approach is a winner, and as such, I'd suggest hanging out on the sidelines in the meantime.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Juno Therapeutics, Inc. Stock Quote
Juno Therapeutics, Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.